Divalproex Sodium
Product Images NDC 53808-1065

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-1065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 250mg (Divalproex 250mg)

Label Image For 250mg (Divalproex 250mg)
A white rectangular label for Divalproex Sodium 250 mg extended-release tablets. The label specifies a quantity of 30 tablets and includes manufacturing details such as batch lot number, expiration date (08-08-2015), and packaging by DOH Central Pharmacy, Tallahassee, FL 32304. It is marked for prescription use only (RX Only).*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
Bar graph comparing percentage outcomes for placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) in two studies, Study 1 (YMRS) and Study 2 (MRS). Study 1 shows 26% for placebo and 60% for DVPX, while Study 2 shows 29% for placebo and 58% for DVPX, highlighting a statistically significant difference (p < 0.05).*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A cumulative percentage plot comparing the percent reduction in CPS rate versus percentage of patients for Divalproex Sodium Delayed-Release Tablets and Placebo groups. The vertical axis represents percent reduction in CPS rate from -100% (worsening) to 100% (improvement), and the horizontal axis represents percentage of patients. The solid line indicates the Divalproex Sodium group, and the dashed line indicates the placebo group, showing greater improvement with Divalproex Sodium.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A line graph depicting percent reduction in CRS rate versus percent of patients for Divalproex Sodium. The graph compares high dose (solid line) and low dose (dashed line) treatments, illustrating patient response distribution from worsening to improvement.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Mean 4-week Migraine Rates' comparing placebo and Divalproex Sodium delayed-release tablets in two studies. The vertical axis represents migraine rates from 0 to 6. Study 1 and Study 2 each show lower migraine rates for Divalproex Sodium delayed-release tablets compared to placebo groups. Dosage footnotes indicate mean doses of 1,087 mg/day for Study 1 and doses of 500 or 1,000 mg/day for Study 2.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure diagram of Divalproex Sodium showing the molecular arrangement including sodium ion and multiple carbon chains. The structure is presented in a repeating polymer form indicated by 'n'.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.